Latest news from Sciele Pharma, A Shionogi Company and Plethora Solutions Holdings PLC on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/pivotal-study-for-psd502-the-first-potential-treatment-for-premature-ejaculation/?sc=rsin /articles/pivotal-study-for-psd502-the-first-potential-treatment-for-premature-ejaculation/?sc=rsin Thu, 19 Nov 2009 08:00:00 EST At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc. today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Sciele Pharma, A Shionogi Company and Plethora Solutions Holdings PLC